{"groups":[{"description":"Testosterone enanthate 50 mg / 75 mg / 100 mg dose administered subcutaneously once each week with possible titration to a higher or lower dose at scheduled intervals during study.","id":"FG000","title":"QST 50 mg / 75 mg / 100 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Missing Completion status"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Sponsor's request"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Met Stopping Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"29"}],"type":"Multiple"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"150"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"137"}],"type":"Completed 12 Week"},{"achievements":[{"groupId":"FG000","numSubjects":"97"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study was designed to ensure a minimum of 100 patients completed a collection of 26 weeks of safety data, and a minimum of 50 patients completed a collection of 52 weeks of safety data. Minimum enrollment goals were exceeded.","recruitmentDetails":"Approximately 150 patients were enrolled in this study. 128 patients completed through at least Week 26, 98 patients completed through Week 52, and 97 patients completed the full study (through the Follow-up Visit)."}